Tricyclo Ring System Patents (Class 514/662)
  • Patent number: 10538482
    Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 21, 2020
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud
    Inventors: Marc Humbert, Sylvia Cohen-Kaminsky, Sébastien Dumas, Gilles Bru-Mercier, Mouad Alami, Jean-Daniel Brion, Samir Messaoudi, Gilles Galvani
  • Patent number: 10245326
    Abstract: A compound is provided that has the formula (II): where R1 in each occurrence is independently H, or C1-C4 alkyl; R2 is a nullity or CH—CH3, R3 is a nullity or C(O)—R6—NH; R6 is C2-C6 alkyl, (CH2CH2—O)n, or (CH(OH)CH2)n; n is an integer of between 1 and 4; R4 is a nullity or NH—R6—C(O); and R5 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, endocannabinoids 1 & 2, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosyl ester, lactic acid, leucine, tryptophan, glutamic acid.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: April 2, 2019
    Inventor: Landon C. G. Miller
  • Publication number: 20150148427
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 28, 2015
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20150126605
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventors: Gregory T. Went, Timothy J. Fultz
  • Publication number: 20150126612
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventors: Gregory T. Went, Timothy J. Fultz
  • Publication number: 20150119465
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: January 7, 2015
    Publication date: April 30, 2015
    Inventors: Gregory T. Went, Timothy J. Fultz, Timothy S. Burkoth
  • Publication number: 20150110880
    Abstract: Provided are an orally disintegrating tablet that quickly disintegrates when it is placed in the mouth or put into water, provides favorable taste, has a sufficient hardness in general production, transportation and use and is excellent in terms of storage stability, and a process for the production of the same which is excellent in terms of industrial production. An orally disintegrating tablet containing a drug, a crystalline cellulose having a bulk density of 0.23 g/cm3 or less (preferably from 0.10 g/cm3 to 0.23 g/cm3), a sugar alcohol and a pregelatinized starch.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 23, 2015
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Gaku Sekiguchi, Ryoichi Hayakawa, Yoshihiro Hara
  • Publication number: 20150087721
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: June 17, 2014
    Publication date: March 26, 2015
    Inventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
  • Publication number: 20150080475
    Abstract: This invention relates to a method of treating opiate addiction caused by microglial over-activation-mediated dopamine (DA) neurons damage, comprising administering a human in need of such treatment 0.01-0.08 mg/kg of 1-amino-3,5-dimethyladamantane hydrochloride orally per day.
    Type: Application
    Filed: September 23, 2014
    Publication date: March 19, 2015
    Inventor: Ru-Band Lu
  • Publication number: 20150065582
    Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 5, 2015
    Inventors: Shashank Mahashabde, Mahendra G. Dedhiya, Anil Chhettry, Ranajoy Sarkar
  • Publication number: 20150056294
    Abstract: Provided herein relates to methods and compositions for preparing a silk microsphere and the resulting silk microsphere. In some embodiments, the methods and compositions described herein are all aqueous, which can be used for encapsulating an active agent in a silk microsphere, while maintaining activity of the active agent during processing. In some embodiments, the resulting silk microsphere can be used for sustained delivery of an active agent encapsulated therein.
    Type: Application
    Filed: April 12, 2013
    Publication date: February 26, 2015
    Inventors: David L. Kaplan, Tuna Yucel, Xiaoqin Wang, Michael Lovett
  • Publication number: 20150057355
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 26, 2015
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20150050294
    Abstract: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Inventor: William G. North
  • Publication number: 20150051292
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 19, 2015
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20150045438
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20150045446
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20150045448
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20150045447
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20150045439
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20150018427
    Abstract: The present invention relates to compounds for use in a method for the treatment or prevention of parvovirus infections in humans and warm-blooded animals, including feline panleukopenia virus (FPV) infections in felids, canine parvovirus type 2 (CPV-2) infections in canines, minute virus of mice (MVM) infections in mice and B19 parvovirus infections in humans.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Applicant: Aratana Therapeutics NV
    Inventors: Nesya Goris, Johan Neyts, Erwin Blomsma, Stefaan Wera, Jérôme Villers, Ainola Billiet, Joeri Auwerx, Veerle Debeurme, Eleonora Kiss, Chloë Swinnen
  • Publication number: 20140378551
    Abstract: The invention relates to an analgesic composition containing memantine. According to the invention, such a composition is administered daily to a human patient having to undergo a surgical operation, over a period ranging from one day to a plurality of days before said surgical operation, in order to prevent and treat the development of post-operative neuropathic pain in this same patient.
    Type: Application
    Filed: October 10, 2012
    Publication date: December 25, 2014
    Applicant: Universite d'Auvergne
    Inventor: Gisele Pickering
  • Publication number: 20140356425
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: December 4, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343152
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343153
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343163
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343164
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140343154
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140336266
    Abstract: Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Applicant: ADAMAS PHARMACEUTICALS, INC.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Publication number: 20140323582
    Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20140303246
    Abstract: Use of an adamantaneamine derivative for the treatment of actinic keratosis.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 9, 2014
    Applicant: MERZ Pharma GmbH & Co. KGaA
    Inventors: Kevin Kiehm, Rainer Pooth, Harry Frank Abts
  • Publication number: 20140288117
    Abstract: The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventor: Bill Piu CHAN
  • Publication number: 20140288185
    Abstract: The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 25, 2014
    Inventors: Srinivasa Rao Akireddy, Jason Speake, Balwinder Singh Bhatti, Daniel Yohannes, John Genus, Yunde Xiao
  • Patent number: 8835507
    Abstract: The present invention relates to adamantane derivatives that are active as antiviral and anti-microbial agents; antiviral or antibacterial compositions comprising adamantane derivatives or pharmaceutically acceptable salts thereof; and methods of preventing or treating viral or bacterial infections in mammalian hosts through the administration of adamantine derivatives or their salts or pharmaceutical compositions comprising the same. In particular, viral infections prevented or treated by the methods of the present invention may include, but are not limited to, those caused by arenavirus or one or more pox viruses, such as vaccinia and/or variola.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 16, 2014
    Assignee: Vymed Corporation
    Inventor: B. Vithal Shetty
  • Publication number: 20140242163
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20140234343
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.
    Type: Application
    Filed: November 12, 2012
    Publication date: August 21, 2014
    Inventors: Bong Hee Lee, Kyung Hee Byun
  • Publication number: 20140213659
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20140200271
    Abstract: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.
    Type: Application
    Filed: July 2, 2013
    Publication date: July 17, 2014
    Applicant: Cerecor, Inc.
    Inventors: Blake Paterson, Mark Ginski, Brendan Canning
  • Publication number: 20140179797
    Abstract: The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.
    Type: Application
    Filed: October 11, 2013
    Publication date: June 26, 2014
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson, Seth Porter, Timothy S. Burkoth
  • Publication number: 20140171436
    Abstract: The present invention is a method of treating antifolate neurotoxicity in a mammal suffering from or at risk of developing antifolate neurotoxicity, which comprises administering to the mammal a therapeutically effective amount of an NMDA antagonist, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 29, 2013
    Publication date: June 19, 2014
    Applicant: Syntrix Biosystems, Inc.
    Inventors: Barton Aron Kamen, John Anthony Zebala
  • Patent number: 8741343
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: June 3, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Patent number: 8685451
    Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: April 1, 2014
    Assignee: Osmotica Kereskedelmi és Szolgáltató KFT
    Inventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
  • Publication number: 20140050784
    Abstract: The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 20, 2014
    Applicants: TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Elena KAGAN, Nitzan SHAHAR, Elina HARONSKY, Gregg R. DEROSA
  • Publication number: 20140004189
    Abstract: Modified release pharmaceutical compositions of memantine or pharmaceutically acceptable salts thereof are described. The compositions of invention are stable, possess improved formulation characteristics and also provide extended therapeutically effective plasma levels over a twenty four hours period. Processes of making these compositions are also described.
    Type: Application
    Filed: January 25, 2012
    Publication date: January 2, 2014
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Sandhya Rajendra Shenoy, Imran Shakoor Ghogari, Vijaykumar Shivajrao Patil
  • Publication number: 20130338113
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Application
    Filed: April 4, 2013
    Publication date: December 19, 2013
    Applicant: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: HAO YI LIANG, FRANCIS CHI, QINGFU XU, BILL PIU CHAN
  • Publication number: 20130323309
    Abstract: A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3:5:1, optionally containing an immediate release coating having memantine where the immediate release coating is applied over the sustained release coating.
    Type: Application
    Filed: February 7, 2012
    Publication date: December 5, 2013
    Applicant: LUPIN LIMITED
    Inventors: Pravin Meghrajji Bhutada, Ashish Ashokrao Deshmukh, Sajeev Chandran, Vineeth Raghavan, Shirishkumar Kulkarni
  • Publication number: 20130317115
    Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.
    Type: Application
    Filed: August 2, 2013
    Publication date: November 28, 2013
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20130310460
    Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
    Type: Application
    Filed: July 23, 2013
    Publication date: November 21, 2013
    Applicant: Forest Laboratories Holdings Ltd.
    Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
  • Publication number: 20130302430
    Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Niranjan RAO, Antonia PERICLOU
  • Publication number: 20130274342
    Abstract: Compositions, methods of making compositions and methods of treating cough are described herein. In some embodiments, the compositions are lozenges comprising memantine and an alkalinizing agent.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 17, 2013
    Applicant: Cerecor, Inc.
    Inventors: Mark GINSKI, Blake PATERSON, Reza MAZHARI, Djelila MEZAACHE
  • Publication number: 20130231391
    Abstract: The present invention relates to adamantane derivatives that are active as antiviral and anti-microbial agents; antiviral or antibacterial compositions comprising adamantane derivatives or pharmaceutically acceptable salts thereof; and methods of preventing or treating viral or bacterial infections in mammalian hosts through the administration of adamantine derivatives or their salts or pharmaceutical compositions comprising the same. In particular, viral infections prevented or treated by the methods of the present invention may include, but are not limited to, those caused by arenavirus or one or more pox viruses, such as vaccinia and/or variola.
    Type: Application
    Filed: February 15, 2013
    Publication date: September 5, 2013
    Applicant: VYMED CORPORATION
    Inventor: B. Vithal SHETTY